Clinical Trial Detail

NCT ID NCT03224767
Title Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Alliance for Clinical Trials in Oncology
Indications

papillary craniopharyngioma

Therapies

Cobimetinib + Vemurafenib

Age Groups: senior adult

Additional content available in CKB BOOST